Editing the Gene Editing Debate: Reassessing the Normative Discussions on Emerging Genetic Technologies

被引:0
|
作者
Oliver Feeney
机构
[1] National University of Ireland (Galway),School of Nursing and Midwifery, University College Cork & Centre of Bioethical Research and Analysis
来源
NanoEthics | 2019年 / 13卷
关键词
CRISPR; Gene-editing; Genetic determinism; ELSI; Ethics; Philosophy; Sociology; Human enhancement;
D O I
暂无
中图分类号
学科分类号
摘要
The revolutionary potential of the CRISPR-Cas9 gene editing technique has created a resurgence in enthusiasm and concern in genetic research perhaps not seen since the mapping of the human genome at the turn of the century. Some such concerns and anxieties revolve around crossing lines between somatic and germline interventions as well as treatment and enhancement applications. Underpinning these concerns, there are familiar concepts of safety, unintended consequences and damage to genetic identity and the creation of designer children through pursuing human enhancement and eugenics. In the policy realm, these morally laden distinctions and anxieties are emerging as the basis for making important and applied measures to respond to the fast-evolving scientific developments. This paper argues that the dominant normative framing for such responses is insufficient for this task. This paper illustrates this insufficiency as arising from a continued reliance on misleading genetic essentialist assumptions that generate groundless speculation and over-reactionary normative responses. This phenomenon is explicit with regard to prospective human (germ line) genetic enhancements. While many normative theorists and state-of-the-art reports continue to gesture toward the influence of environmental and social influences on a person and their traits and capacities, this recognition does not extend to the substance of the arguments themselves which tend to revert to the debunked genetic determinist framework. Given the above, this paper argues that there is a pressing need for a more central role for sociological input into particular aspects of this “enhancement myth” in order to give added weight, detail and substance to these environmental influences and influence from social structures.
引用
收藏
页码:233 / 243
页数:10
相关论文
共 50 条
  • [31] Responsible Use of Human Gene-Editing Technologies
    Dzau, Victor J.
    Cicerone, Ralph J.
    HUMAN GENE THERAPY, 2015, 26 (07) : 411 - 412
  • [32] Multiplexed CRISPR technologies for gene editing and transcriptional regulation
    Nicholas S. McCarty
    Alicia E. Graham
    Lucie Studená
    Rodrigo Ledesma-Amaro
    Nature Communications, 11
  • [33] The CRISPR-Cas toolbox and gene editing technologies
    Liu, Guanwen
    Lin, Qiupeng
    Jin, Shuai
    Gao, Caixia
    MOLECULAR CELL, 2022, 82 (02) : 333 - 347
  • [34] Gene Editing Technologies for Sugarcane Improvement: Opportunities and Limitations
    Chakravarthi Mohan
    Mona Easterling
    Yuan-Yeu Yau
    Sugar Tech, 2022, 24 : 369 - 385
  • [35] Emerging Maxims for the Ethics of Preventive Human Gene Editing
    Cadigan, R. Jean
    Waltz, Margaret
    Conley, John
    Henderson, Gail
    MacKay, Doug
    Major, Rami
    Walker, Rebecca
    Juengst, Eric
    MOLECULAR THERAPY, 2023, 31 (04) : 541 - 541
  • [36] Gene Editing Technologies for Sugarcane Improvement: Opportunities and Limitations
    Mohan, Chakravarthi
    Easterling, Mona
    Yau, Yuan-Yeu
    SUGAR TECH, 2022, 24 (01) : 369 - 385
  • [37] Genome-editing technologies for gene correction of hemophilia
    Park, Chul-Yong
    Lee, Dongjin R.
    Sung, Jin Jea
    Kim, Dong-Wook
    HUMAN GENETICS, 2016, 135 (09) : 977 - 981
  • [38] Genome engineering via gene editing technologies in microalgae
    Jeong, Byeong-ryool
    Jang, Junhwan
    Jin, EonSeon
    BIORESOURCE TECHNOLOGY, 2023, 373
  • [39] Gene editing: from technologies to applications in research and beyond
    Wensheng Wei
    Caixia Gao
    Science China Life Sciences, 2022, 65 : 657 - 659
  • [40] Genome-editing Technologies for Gene and Cell Therapy
    Maeder, Morgan L.
    Gersbach, Charles A.
    MOLECULAR THERAPY, 2016, 24 (03) : 430 - 446